Dare sees R&D expenses for future quarters lower than Q1 R&D expenses

Research and development expenses: $3.3 million in 1Q-2024 as compared to $5.0 million in 1Q-2023, a 34% decrease compared to Q1-2023. Close-out expenses related to the Phase 2b RESPOND clinical study of Sildenafil Cream and other clinical studies conducted in 2023 contributed significantly to Dare‘s 1Q-2024 R&D expenses, which will not be the case in future quarters. Until Dare commences a Sildenafil Cream Phase 3 clinical study, Dare expects R&D expenses for future quarters to be lower than its 1Q-2024 R&D expenses.